Our History

Major Milestones

Since establishing its U.S. presence, Lupin has recorded steady growth and consolidated its presence in the local market as the third major pharmaceutical company, measured by number of filled prescriptions.

2003
2004
2005
2009
2010
2015
2016
2017
2018
2023
2024

2003

Lupin Pharmaceuticals Inc. U.S. was formed for commercialization activities in the U.S.

2004

Commences U.S. Branded Business with the launch of Suprax®

2005

Receives US FDA approval for New Lovastatin Plant at Tarapur
Receives US FDA approval for Goa Finished Dosage facility
Launches its Generics Business in the U.S.

2009

Acquires the U.S. Rights for Antara®

2010

Becomes the 5th largest generic player in the U.S.

2015

Inaugurates new Center of Excellence for Inhalation Research in Coral Springs, Florida

2016

By acquiring Novel Laboratories, Inc., Lupin created Lupin Somerset, Lupin’s first U.S. based commercial manufacturing facility
Completes acquisition of U.S. based GAVIS Pharmaceuticals LLC

2017

Acquires Symbiomix Therapeutics, LLC in New Jersey for the launch of Solosec®
Signs deal with Illinois-based AbbVie offering exclusive rights to develop and commercialize Lupin’s MALT1 inhibitors (oncology)

2018

Solosec® (secnidazole) launched in the U.S.

2023

Lupin launches Tiotropium Dry Powder Inhaler for the treatment of COPD in the United States
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD Foundation to expand access to medication for COPD patients

2024

Lupin Enters the S&P Global Sustainability Yearbook 2024

Smart Guide

Our History

Major Milestones

Search Product